| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, B-Cell | 8 | 2024 | 148 | 3.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 24 | 2024 | 1193 | 3.020 |
Why?
|
| Immunotherapy, Adoptive | 15 | 2024 | 899 | 2.050 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2024 | 612 | 1.500 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 | 2024 | 175 | 1.480 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2024 | 168 | 1.460 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2023 | 32 | 1.370 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2022 | 63 | 1.320 |
Why?
|
| Antigens, CD19 | 6 | 2024 | 182 | 1.230 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2024 | 151 | 1.150 |
Why?
|
| Graft vs Host Disease | 10 | 2024 | 621 | 0.980 |
Why?
|
| Hematologic Neoplasms | 5 | 2024 | 294 | 0.930 |
Why?
|
| Aged | 50 | 2025 | 21476 | 0.900 |
Why?
|
| Lymphoma, Follicular | 3 | 2020 | 30 | 0.900 |
Why?
|
| Middle Aged | 53 | 2025 | 28952 | 0.820 |
Why?
|
| Hodgkin Disease | 3 | 2020 | 295 | 0.780 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1351 | 0.750 |
Why?
|
| Primary Myelofibrosis | 2 | 2020 | 52 | 0.730 |
Why?
|
| Humans | 97 | 2025 | 133271 | 0.720 |
Why?
|
| Antigens, CD20 | 2 | 2020 | 40 | 0.720 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 25 | 0.680 |
Why?
|
| Machine Learning | 5 | 2025 | 345 | 0.680 |
Why?
|
| Transplantation, Autologous | 8 | 2024 | 288 | 0.680 |
Why?
|
| Aftercare | 1 | 2021 | 157 | 0.670 |
Why?
|
| Transplantation Conditioning | 9 | 2020 | 300 | 0.670 |
Why?
|
| Mouth Diseases | 1 | 2020 | 16 | 0.670 |
Why?
|
| Adult | 46 | 2025 | 31650 | 0.650 |
Why?
|
| Delirium | 3 | 2025 | 63 | 0.640 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 126 | 0.590 |
Why?
|
| SEER Program | 1 | 2019 | 222 | 0.580 |
Why?
|
| Retrospective Studies | 35 | 2025 | 17556 | 0.580 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2018 | 511 | 0.580 |
Why?
|
| Rituximab | 5 | 2024 | 165 | 0.570 |
Why?
|
| Microtubule Proteins | 1 | 2018 | 30 | 0.570 |
Why?
|
| Aged, 80 and over | 18 | 2025 | 7138 | 0.570 |
Why?
|
| Male | 56 | 2025 | 65523 | 0.570 |
Why?
|
| Acetyltransferases | 1 | 2018 | 93 | 0.570 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2024 | 43 | 0.570 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2018 | 52 | 0.560 |
Why?
|
| Transplantation, Homologous | 5 | 2019 | 653 | 0.560 |
Why?
|
| Pyrazoles | 6 | 2024 | 334 | 0.550 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 43 | 0.550 |
Why?
|
| Microtubules | 1 | 2018 | 132 | 0.550 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2018 | 128 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 1310 | 0.530 |
Why?
|
| Standard of Care | 1 | 2018 | 136 | 0.530 |
Why?
|
| Female | 55 | 2025 | 71439 | 0.510 |
Why?
|
| T-Lymphocytes | 6 | 2024 | 1770 | 0.500 |
Why?
|
| Lymphoma | 4 | 2023 | 331 | 0.500 |
Why?
|
| Sulfonamides | 4 | 2024 | 289 | 0.490 |
Why?
|
| Pyrimidines | 7 | 2024 | 420 | 0.480 |
Why?
|
| Recurrence | 6 | 2024 | 1469 | 0.460 |
Why?
|
| Clinical Deterioration | 2 | 2025 | 14 | 0.450 |
Why?
|
| Doxorubicin | 3 | 2024 | 301 | 0.450 |
Why?
|
| Multiple Myeloma | 3 | 2024 | 204 | 0.450 |
Why?
|
| Medicare | 1 | 2018 | 468 | 0.440 |
Why?
|
| Geriatric Assessment | 2 | 2025 | 191 | 0.430 |
Why?
|
| Periprosthetic Fractures | 2 | 2024 | 11 | 0.430 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2015 | 189 | 0.420 |
Why?
|
| Antibodies, Bispecific | 2 | 2024 | 52 | 0.410 |
Why?
|
| Antineoplastic Agents | 5 | 2024 | 1849 | 0.400 |
Why?
|
| Neoplasms | 3 | 2024 | 2984 | 0.400 |
Why?
|
| Cyclophosphamide | 6 | 2024 | 426 | 0.390 |
Why?
|
| Treatment Outcome | 19 | 2025 | 13102 | 0.390 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 571 | 0.390 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2022 | 504 | 0.390 |
Why?
|
| Allografts | 3 | 2023 | 199 | 0.360 |
Why?
|
| Cell Proliferation | 2 | 2018 | 2559 | 0.350 |
Why?
|
| Survival Analysis | 6 | 2021 | 1584 | 0.350 |
Why?
|
| Inpatients | 3 | 2025 | 555 | 0.350 |
Why?
|
| Electronic Health Records | 4 | 2025 | 804 | 0.340 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2024 | 128 | 0.340 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1363 | 0.330 |
Why?
|
| Etoposide | 3 | 2024 | 120 | 0.330 |
Why?
|
| Prednisone | 3 | 2024 | 256 | 0.320 |
Why?
|
| Vincristine | 3 | 2024 | 196 | 0.320 |
Why?
|
| Mass Screening | 2 | 2025 | 835 | 0.300 |
Why?
|
| Young Adult | 10 | 2024 | 9925 | 0.300 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 2 | 2019 | 12 | 0.300 |
Why?
|
| Survival Rate | 5 | 2024 | 2208 | 0.300 |
Why?
|
| Influenza, Human | 1 | 2015 | 700 | 0.300 |
Why?
|
| Hospitals | 4 | 2024 | 441 | 0.300 |
Why?
|
| Melphalan | 2 | 2018 | 46 | 0.290 |
Why?
|
| Heart Failure | 1 | 2021 | 2428 | 0.290 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 306 | 0.280 |
Why?
|
| Hospitalization | 6 | 2024 | 1921 | 0.280 |
Why?
|
| Pneumonia | 2 | 2023 | 341 | 0.270 |
Why?
|
| Boron Compounds | 2 | 2024 | 34 | 0.260 |
Why?
|
| Adenine | 3 | 2024 | 123 | 0.250 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 288 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 829 | 0.240 |
Why?
|
| Smad2 Protein | 2 | 2016 | 54 | 0.240 |
Why?
|
| Glycine | 2 | 2024 | 172 | 0.240 |
Why?
|
| Neoplasms, Second Primary | 2 | 2024 | 150 | 0.230 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2025 | 15 | 0.230 |
Why?
|
| Gastrointestinal Diseases | 2 | 2019 | 353 | 0.220 |
Why?
|
| Sulfides | 1 | 2024 | 24 | 0.220 |
Why?
|
| Neovascularization, Physiologic | 2 | 2017 | 225 | 0.220 |
Why?
|
| Acetates | 1 | 2024 | 80 | 0.220 |
Why?
|
| Cyclopropanes | 1 | 2024 | 71 | 0.220 |
Why?
|
| Delayed Graft Function | 1 | 2024 | 7 | 0.220 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2024 | 11 | 0.220 |
Why?
|
| Cold Ischemia | 1 | 2024 | 23 | 0.210 |
Why?
|
| Genetics, Population | 1 | 2025 | 192 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 5 | 2024 | 2576 | 0.210 |
Why?
|
| Femoral Fractures | 1 | 2024 | 35 | 0.210 |
Why?
|
| Intensive Care Units | 4 | 2025 | 542 | 0.210 |
Why?
|
| Graft Survival | 2 | 2024 | 482 | 0.210 |
Why?
|
| Early Diagnosis | 1 | 2024 | 199 | 0.210 |
Why?
|
| Quinolines | 1 | 2024 | 115 | 0.210 |
Why?
|
| Metformin | 1 | 2025 | 166 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 294 | 0.210 |
Why?
|
| Prognosis | 4 | 2024 | 5042 | 0.210 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 679 | 0.200 |
Why?
|
| Unrelated Donors | 2 | 2024 | 70 | 0.200 |
Why?
|
| Surgical Procedures, Operative | 1 | 2025 | 190 | 0.200 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2023 | 86 | 0.200 |
Why?
|
| Sepsis | 3 | 2024 | 523 | 0.200 |
Why?
|
| Hypoglycemic Agents | 2 | 2025 | 492 | 0.200 |
Why?
|
| Rheumatic Diseases | 1 | 2024 | 73 | 0.200 |
Why?
|
| Orthopedics | 1 | 2024 | 78 | 0.200 |
Why?
|
| Ivermectin | 1 | 2022 | 8 | 0.200 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 592 | 0.200 |
Why?
|
| Hip Fractures | 1 | 2023 | 74 | 0.190 |
Why?
|
| Tumor Lysis Syndrome | 2 | 2019 | 11 | 0.190 |
Why?
|
| Autografts | 2 | 2019 | 29 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 158 | 0.190 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 965 | 0.190 |
Why?
|
| United States | 8 | 2024 | 11723 | 0.180 |
Why?
|
| Transplantation, Haploidentical | 2 | 2019 | 17 | 0.180 |
Why?
|
| Risk Factors | 9 | 2025 | 10956 | 0.180 |
Why?
|
| Cohort Studies | 7 | 2025 | 5196 | 0.180 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 343 | 0.180 |
Why?
|
| Budesonide | 1 | 2021 | 20 | 0.180 |
Why?
|
| Piperidines | 2 | 2020 | 241 | 0.180 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2023 | 111 | 0.180 |
Why?
|
| Data Accuracy | 1 | 2021 | 34 | 0.180 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2024 | 153 | 0.180 |
Why?
|
| Information Storage and Retrieval | 1 | 2021 | 66 | 0.170 |
Why?
|
| Renal Insufficiency | 1 | 2023 | 256 | 0.170 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 15 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 216 | 0.170 |
Why?
|
| Fungemia | 1 | 2020 | 23 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 317 | 0.170 |
Why?
|
| COS Cells | 2 | 2018 | 286 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 543 | 0.170 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2020 | 107 | 0.170 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2020 | 15 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 79 | 0.170 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2020 | 7 | 0.170 |
Why?
|
| Neuromuscular Blockade | 1 | 2020 | 6 | 0.170 |
Why?
|
| Neostigmine | 1 | 2020 | 6 | 0.170 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 123 | 0.170 |
Why?
|
| Respiration Disorders | 1 | 2020 | 33 | 0.170 |
Why?
|
| Databases, Factual | 3 | 2025 | 1240 | 0.170 |
Why?
|
| Tissue Donors | 1 | 2024 | 507 | 0.170 |
Why?
|
| Prospective Studies | 5 | 2025 | 6582 | 0.160 |
Why?
|
| Gram-Negative Bacteria | 1 | 2020 | 74 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 104 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 32 | 0.160 |
Why?
|
| Anti-Infective Agents | 1 | 2022 | 276 | 0.160 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 97 | 0.160 |
Why?
|
| Postoperative Complications | 3 | 2024 | 3171 | 0.160 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 2092 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 211 | 0.160 |
Why?
|
| Febrile Neutropenia | 1 | 2019 | 15 | 0.160 |
Why?
|
| Propranolol | 1 | 2020 | 121 | 0.160 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 384 | 0.160 |
Why?
|
| HeLa Cells | 2 | 2018 | 839 | 0.150 |
Why?
|
| Steroids | 1 | 2020 | 211 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 469 | 0.150 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2019 | 47 | 0.150 |
Why?
|
| ROC Curve | 3 | 2025 | 606 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 5436 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 314 | 0.150 |
Why?
|
| Zearalenone | 1 | 2018 | 5 | 0.150 |
Why?
|
| Dioxoles | 1 | 2018 | 12 | 0.150 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 63 | 0.140 |
Why?
|
| Cell Line | 3 | 2018 | 2855 | 0.140 |
Why?
|
| Health Education | 1 | 2020 | 232 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2024 | 575 | 0.140 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 35 | 0.140 |
Why?
|
| Mice, Inbred ICR | 1 | 2018 | 154 | 0.140 |
Why?
|
| Cytological Techniques | 1 | 2017 | 18 | 0.140 |
Why?
|
| Siblings | 1 | 2019 | 202 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2020 | 212 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 62 | 0.140 |
Why?
|
| Heart Arrest | 1 | 2022 | 376 | 0.140 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 157 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 136 | 0.140 |
Why?
|
| Acetylation | 1 | 2018 | 196 | 0.140 |
Why?
|
| Benzamides | 1 | 2018 | 126 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2021 | 521 | 0.140 |
Why?
|
| Etanercept | 1 | 2017 | 47 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 384 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 1837 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2019 | 202 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 196 | 0.130 |
Why?
|
| Disease Management | 2 | 2018 | 565 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2017 | 63 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 1049 | 0.130 |
Why?
|
| Age Factors | 3 | 2018 | 2954 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 400 | 0.130 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 46 | 0.130 |
Why?
|
| Outpatients | 3 | 2024 | 275 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2022 | 750 | 0.130 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 53 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2017 | 362 | 0.130 |
Why?
|
| Adolescent | 6 | 2024 | 20552 | 0.130 |
Why?
|
| Bacteremia | 1 | 2020 | 430 | 0.130 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 314 | 0.120 |
Why?
|
| Remission Induction | 3 | 2023 | 307 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 720 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2018 | 619 | 0.120 |
Why?
|
| Mitochondrial Dynamics | 1 | 2016 | 55 | 0.120 |
Why?
|
| Plant Extracts | 1 | 2017 | 138 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2019 | 431 | 0.120 |
Why?
|
| Autophagy | 2 | 2017 | 431 | 0.120 |
Why?
|
| GTP Phosphohydrolases | 1 | 2016 | 156 | 0.120 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 156 | 0.120 |
Why?
|
| Endothelium | 1 | 2015 | 70 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 225 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 256 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 706 | 0.110 |
Why?
|
| Age Distribution | 1 | 2015 | 426 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 170 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1164 | 0.110 |
Why?
|
| Hospitals, University | 2 | 2025 | 107 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2020 | 551 | 0.110 |
Why?
|
| Amino Acid Motifs | 1 | 2014 | 212 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2020 | 700 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1307 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 2014 | 98 | 0.110 |
Why?
|
| Logistic Models | 2 | 2016 | 1863 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 806 | 0.100 |
Why?
|
| Illinois | 2 | 2024 | 18 | 0.100 |
Why?
|
| Plasmacytoma | 1 | 2013 | 9 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 772 | 0.100 |
Why?
|
| Veterans | 1 | 2024 | 1782 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2014 | 441 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 498 | 0.090 |
Why?
|
| Cytokines | 1 | 2018 | 1378 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 225 | 0.090 |
Why?
|
| Phenotype | 1 | 2021 | 4577 | 0.090 |
Why?
|
| Obesity | 2 | 2024 | 2438 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2024 | 330 | 0.090 |
Why?
|
| Calcineurin Inhibitors | 2 | 2024 | 29 | 0.090 |
Why?
|
| Insurance, Health | 2 | 2024 | 145 | 0.090 |
Why?
|
| Mice | 5 | 2023 | 18929 | 0.090 |
Why?
|
| Blood Culture | 2 | 2021 | 36 | 0.090 |
Why?
|
| Mitochondria | 1 | 2016 | 755 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2018 | 4915 | 0.090 |
Why?
|
| Time Factors | 4 | 2022 | 6545 | 0.080 |
Why?
|
| Organ Transplantation | 1 | 2013 | 182 | 0.080 |
Why?
|
| Exercise | 3 | 2024 | 873 | 0.080 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 498 | 0.080 |
Why?
|
| Reoperation | 2 | 2024 | 856 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 293 | 0.080 |
Why?
|
| Comorbidity | 1 | 2015 | 1622 | 0.080 |
Why?
|
| Consensus | 2 | 2024 | 724 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2015 | 824 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2024 | 1660 | 0.080 |
Why?
|
| Nitriles | 2 | 2020 | 155 | 0.080 |
Why?
|
| Animals | 6 | 2024 | 36195 | 0.080 |
Why?
|
| Busulfan | 2 | 2020 | 45 | 0.070 |
Why?
|
| Methotrexate | 2 | 2024 | 355 | 0.070 |
Why?
|
| Vidarabine | 2 | 2020 | 80 | 0.070 |
Why?
|
| Tacrolimus | 2 | 2020 | 105 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2024 | 1100 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2020 | 835 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 555 | 0.070 |
Why?
|
| Incidence | 3 | 2019 | 3391 | 0.060 |
Why?
|
| Endoglin | 2 | 2015 | 32 | 0.060 |
Why?
|
| Leukotriene Antagonists | 1 | 2024 | 18 | 0.060 |
Why?
|
| Latin America | 1 | 2025 | 98 | 0.060 |
Why?
|
| Drug Industry | 1 | 2024 | 49 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 1 | 2024 | 175 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 68 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2024 | 83 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2024 | 250 | 0.050 |
Why?
|
| Culturally Competent Care | 1 | 2024 | 52 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2025 | 317 | 0.050 |
Why?
|
| Knee | 1 | 2024 | 22 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2025 | 168 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2024 | 151 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2024 | 135 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2024 | 132 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2023 | 169 | 0.050 |
Why?
|
| Haplotypes | 1 | 2025 | 545 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 134 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2024 | 125 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 77 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2022 | 31 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2024 | 171 | 0.050 |
Why?
|
| Frailty | 1 | 2025 | 134 | 0.050 |
Why?
|
| Knee Joint | 1 | 2024 | 171 | 0.050 |
Why?
|
| Vital Signs | 1 | 2022 | 23 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2020 | 1411 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 168 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2023 | 293 | 0.050 |
Why?
|
| Hypertension | 2 | 2024 | 1402 | 0.050 |
Why?
|
| Endothelial Cells | 2 | 2017 | 539 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2015 | 8628 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2024 | 687 | 0.050 |
Why?
|
| Neutropenia | 1 | 2023 | 205 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2025 | 786 | 0.050 |
Why?
|
| Chicago | 1 | 2021 | 21 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2023 | 285 | 0.050 |
Why?
|
| Life Style | 1 | 2024 | 457 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 562 | 0.040 |
Why?
|
| Organ Dysfunction Scores | 1 | 2021 | 52 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2016 | 1706 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2021 | 139 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 322 | 0.040 |
Why?
|
| DNA Topoisomerase IV | 1 | 2020 | 13 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2024 | 248 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 101 | 0.040 |
Why?
|
| DNA Gyrase | 1 | 2020 | 26 | 0.040 |
Why?
|
| Asia, Western | 1 | 2020 | 4 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 418 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2022 | 463 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2021 | 129 | 0.040 |
Why?
|
| Patient Admission | 1 | 2021 | 191 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2024 | 566 | 0.040 |
Why?
|
| Software | 1 | 2025 | 732 | 0.040 |
Why?
|
| Infant | 1 | 2015 | 13237 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 374 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2023 | 519 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2020 | 319 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2020 | 262 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2015 | 14865 | 0.040 |
Why?
|
| Cultural Competency | 1 | 2020 | 53 | 0.040 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2020 | 103 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2022 | 415 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2025 | 2288 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2019 | 60 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 607 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 181 | 0.040 |
Why?
|
| Propylene Glycol | 1 | 2018 | 9 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 166 | 0.040 |
Why?
|
| Exanthema | 1 | 2019 | 71 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 356 | 0.040 |
Why?
|
| Myeloablative Agonists | 1 | 2018 | 20 | 0.040 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2018 | 2 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 963 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2020 | 500 | 0.040 |
Why?
|
| Genome, Human | 1 | 2025 | 1339 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2017 | 82 | 0.030 |
Why?
|
| Critical Care | 1 | 2023 | 698 | 0.030 |
Why?
|
| Magnoliaceae | 1 | 2017 | 1 | 0.030 |
Why?
|
| Binding Sites | 1 | 2020 | 1378 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 345 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2017 | 296 | 0.030 |
Why?
|
| Fever | 1 | 2019 | 312 | 0.030 |
Why?
|
| New York City | 1 | 2016 | 65 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2018 | 373 | 0.030 |
Why?
|
| Lipids | 1 | 2020 | 565 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 50 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2018 | 541 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 432 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2024 | 906 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2141 | 0.030 |
Why?
|
| Superoxides | 1 | 2016 | 132 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 335 | 0.030 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2016 | 63 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2016 | 203 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1236 | 0.030 |
Why?
|
| Body Weight | 1 | 2020 | 1035 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 150 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2854 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 757 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2015 | 30 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1714 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 281 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 1174 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 3986 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1214 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 520 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 453 | 0.030 |
Why?
|
| Child | 1 | 2015 | 25851 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 396 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 542 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 250 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2020 | 604 | 0.030 |
Why?
|
| Activin Receptors, Type II | 1 | 2014 | 34 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 509 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3719 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 2629 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 436 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 546 | 0.030 |
Why?
|
| Zebrafish | 1 | 2017 | 419 | 0.030 |
Why?
|
| DNA Primers | 1 | 2015 | 656 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2016 | 292 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 1095 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 175 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2246 | 0.030 |
Why?
|
| Anticholesteremic Agents | 1 | 2016 | 247 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1136 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2014 | 106 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 362 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1156 | 0.030 |
Why?
|
| Triglycerides | 1 | 2016 | 616 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 2165 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1166 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3046 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 410 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 1254 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1471 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2013 | 57 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1463 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 545 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 609 | 0.020 |
Why?
|
| Diet | 1 | 2020 | 1170 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 3794 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1325 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2016 | 1185 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1851 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 1582 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 481 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2016 | 629 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 943 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2016 | 815 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 3153 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3418 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 1711 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 3131 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 937 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 4823 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3863 | 0.010 |
Why?
|